MD HB1654 | 2020 | Regular Session

Note: Carry Foward to future HB1125

Status

Spectrum: Partisan Bill (Republican 3-0)
Status: Introduced on March 2 2020 - 25% progression, died in committee
Action: 2020-03-02 - First Reading House Rules and Executive Nominations
Pending: House Rules and Executive Nominations Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Requiring a prescriber to notify the Prescription Drug Monitoring Program as to whether the prescriber has received education regarding the risks of opioid use, is aware that an opioid overdose reversal drug is available, and has prescribed or dispensed an opioid overdose reversal drug if the prescriber prescribes or dispenses an opioid in a dosage of 50 morphine milligram equivalents or more; and prohibiting a prescriber from being required to make a certain notification more than once.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Prescription Drug Monitoring Program - Prescribers of Opioids - Notification Requirement

Sponsors


History

DateChamberAction
2020-03-02HouseFirst Reading House Rules and Executive Nominations

Same As/Similar To

HB1654 (Carry Over) 2020-03-02 - First Reading House Rules and Executive Nominations

Subjects


Code Citations

ChapterArticleSectionCitation TypeStatute Text
Health - General212A-02(n/a)See Bill Text
Health - General212A-04.2(n/a)See Bill Text

Maryland State Sources


Bill Comments

feedback